Education
About Us
Working with TipRanks
Follow Us
CytoMed Therapeutics Limited (GDTC)
:GDTC
RESEARCH TOOLSreports
GDTC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.20 - $4.05
Previous CloseN/A
Volume107.31K
Average Volume (3M)6.32K
Market Cap
$27.74M
Enterprise Value$33.62M
Total Cash (Recent Filing)$3.64M
Total Debt (Recent Filing)$463.25K
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Nov 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding12,550,000
10 Day Avg. Volume5,908
30 Day Avg. Volume6,319
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)72.61
Price to Sales (P/S)0.00
P/FCF Ratio-22.76
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue33.66
Enterprise Value/Gross Profit-271.41
Enterprise Value/Ebitda-2.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CytoMed Therapeutics Limited News
PremiumCompany Announcements
CytoMed Therapeutics Issues Shares to Executives as Compensation
PremiumCompany Announcements
CytoMed Therapeutics Schedules AGM for June 2025
PremiumCompany Announcements
CytoMed Therapeutics Reports 2024 Financial Results and Clinical Progress
PremiumCompany Announcements
CytoMed Therapeutics Announces 2024 Financial Results and Clinical Advances
PremiumCompany Announcements
CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in IndiaOptions Prices
Currently, No data available
---
Ownership Overview
26.57% Insiders
0.04%
Mutual Funds
0.04% Other Institutional Investors
73.35% Public Companies and
Individual Investors
GDTC FAQ
What was CytoMed Therapeutics Limited’s price range in the past 12 months?
CytoMed Therapeutics Limited lowest stock price was $1.20 and its highest was $4.05 in the past 12 months.
What is CytoMed Therapeutics Limited’s market cap?
CytoMed Therapeutics Limited’s market cap is $27.74M.
When is CytoMed Therapeutics Limited’s upcoming earnings report date?
CytoMed Therapeutics Limited’s upcoming earnings report date is Nov 14, 2025 which is in 123 days.
How were CytoMed Therapeutics Limited’s earnings last quarter?
CytoMed Therapeutics Limited released its earnings results on Apr 28, 2025. The company reported -$0.093 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.093.
Is CytoMed Therapeutics Limited overvalued?
According to Wall Street analysts CytoMed Therapeutics Limited’s price is currently Overvalued.
Does CytoMed Therapeutics Limited pay dividends?
CytoMed Therapeutics Limited does not currently pay dividends.
What is CytoMed Therapeutics Limited’s EPS estimate?
CytoMed Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoMed Therapeutics Limited have?
CytoMed Therapeutics Limited has 12,550,000 shares outstanding.
What happened to CytoMed Therapeutics Limited’s price movement after its last earnings report?
CytoMed Therapeutics Limited reported an EPS of -$0.093 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.245%.
Which hedge fund is a major shareholder of CytoMed Therapeutics Limited?
Currently, no hedge funds are holding shares in GDTC
CytoMed Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Sold Shares
Worth $171.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.80%
12-Months-Change
Fundamentals
Return on Equity
-24.97%
Trailing 12-Months
Asset Growth
-21.30%
Trailing 12-Months
Company Description
CytoMed Therapeutics Limited
CytoMed Therapeutics Limited (GDTC) is a biotechnology company focused on the development and commercialization of innovative cell-based therapies for the treatment of various diseases. The company is engaged in research and development activities primarily in the field of regenerative medicine, using advanced cellular technologies to address unmet medical needs. CytoMed's core products include a pipeline of therapeutic candidates designed to harness the power of cellular therapy to restore health and improve patient outcomes.
Technical Analysis
Tempest Therapeutics
―
VYNE Therapeutics
―
Clene
―
PolyPid
―
Barinthus Biotherapeutics
―